Comparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. 1998

J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
Rega Institute for Medical Research, Katholieke Universiteit Leuven, Belgium. schmit.jc@chl.lu

The performance to detect drug resistance mutations in the reverse transcriptase gene of HIV-1 was compared for direct solid phase sequencing, selective polymerase chain reaction (PCR) using the amplification refractory mutation system (ARMS) and the new line probe assay (LIPA) HIV-1 RT. The three tests were undertaken on 50 plasma samples from 25 treatment-experienced patients under combination therapy with dideoxynucleoside analogues. LiPA HIV-1 RT gave interpretable results in 80 to 96% of the samples depending on the codon of interest. In 2% of the samples a failure to amplify resulted in uninterpretable results for sequencing. ARMS gave no result in seven samples (14%). Overall, there was a 73 to 100% concordance between the three methods. In this study, LiPA HIV-1 RT proved to be an accurate and reliable alternative to DNA sequencing for the detection of drug resistance mutations in patient samples.

UI MeSH Term Description Entries
D009154 Mutation Any detectable and heritable change in the genetic material that causes a change in the GENOTYPE and which is transmitted to daughter cells and to succeeding generations. Mutations
D003062 Codon A set of three nucleotides in a protein coding sequence that specifies individual amino acids or a termination signal (CODON, TERMINATOR). Most codons are universal, but some organisms do not produce the transfer RNAs (RNA, TRANSFER) complementary to all codons. These codons are referred to as unassigned codons (CODONS, NONSENSE). Codon, Sense,Sense Codon,Codons,Codons, Sense,Sense Codons
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005838 Genotype The genetic constitution of the individual, comprising the ALLELES present at each GENETIC LOCUS. Genogroup,Genogroups,Genotypes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015342 DNA Probes Species- or subspecies-specific DNA (including COMPLEMENTARY DNA; conserved genes, whole chromosomes, or whole genomes) used in hybridization studies in order to identify microorganisms, to measure DNA-DNA homologies, to group subspecies, etc. The DNA probe hybridizes with a specific mRNA, if present. Conventional techniques used for testing for the hybridization product include dot blot assays, Southern blot assays, and DNA:RNA hybrid-specific antibody tests. Conventional labels for the DNA probe include the radioisotope labels 32P and 125I and the chemical label biotin. The use of DNA probes provides a specific, sensitive, rapid, and inexpensive replacement for cell culture techniques for diagnosing infections. Chromosomal Probes,DNA Hybridization Probe,DNA Probe,Gene Probes, DNA,Conserved Gene Probes,DNA Hybridization Probes,Whole Chromosomal Probes,Whole Genomic DNA Probes,Chromosomal Probes, Whole,DNA Gene Probes,Gene Probes, Conserved,Hybridization Probe, DNA,Hybridization Probes, DNA,Probe, DNA,Probe, DNA Hybridization,Probes, Chromosomal,Probes, Conserved Gene,Probes, DNA,Probes, DNA Gene,Probes, DNA Hybridization,Probes, Whole Chromosomal
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
March 1999, Journal of medical virology,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
October 1993, Nature,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
September 2010, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
December 2019, JAMA,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
September 2020, Microbial pathogenesis,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
May 2006, Journal of virological methods,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
July 2019, The Journal of molecular diagnostics : JMD,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
January 2018, PloS one,
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
June 2014, AIDS (London, England),
J C Schmit, and L Ruiz, and L Stuyver, and K Van Laethem, and I Vanderlinden, and T Puig, and R Rossau, and J Desmyter, and E De Clercq, and B Clotet, and A M Vandamme
January 2011, Asian Pacific journal of cancer prevention : APJCP,
Copied contents to your clipboard!